相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
N. Shinohara et al.
BRITISH JOURNAL OF CANCER (2011)
RAF inhibition and induction of cutaneous squamous cell carcinoma
Caroline Robert et al.
CURRENT OPINION IN ONCOLOGY (2011)
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
Chun-Fang Xu et al.
JOURNAL OF HEPATOLOGY (2011)
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
L. M. Riesenbeck et al.
WORLD JOURNAL OF UROLOGY (2011)
Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
Dorothy A. White et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Incidence of brain metastases in renal cell carcinoma treated with sorafenib
C. Massard et al.
ANNALS OF ONCOLOGY (2010)
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management
M. Mandala et al.
ANNALS OF ONCOLOGY (2010)
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
C-F Xu et al.
BRITISH JOURNAL OF CANCER (2010)
Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America
Walter M. Stadler et al.
CANCER (2010)
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
Manuela Schmidinger et al.
CANCER TREATMENT REVIEWS (2010)
Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET
Thomas E. Hutson et al.
EUROPEAN JOURNAL OF CANCER (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Endoscopic Management of Colonic Perforation Owing to Angiogenesis Inhibitors
Salah Ezzedine et al.
SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES (2010)
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Hideaki Miyake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Thrombosis associated with angiogenesis inhibitors
Francesca Elice et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
R. Kumar et al.
BRITISH JOURNAL OF CANCER (2009)
A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer
Robert J. Amato et al.
CANCER (2009)
Tolerability of first-line therapy for metastatic renal cell carcinoma
Camillo Porta et al.
CANCER TREATMENT REVIEWS (2009)
Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
Zita Dubauskas et al.
CLINICAL GENITOURINARY CANCER (2009)
Medroxyprogesterone acetate in the management of cancer cachexia
Clelia Madeddu et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma
Thomas W. Flaig et al.
INVESTIGATIONAL NEW DRUGS (2009)
Diagnosis and Management of Hypertension in Advanced Renal Cell Carcinoma: Prospective Evaluation of an Algorithm in Patients Treated with Sunitinib
A. Bamias et al.
JOURNAL OF CHEMOTHERAPY (2009)
Could Rigorous Diagnosis and Management of Hypertension Reduce Cardiac Events in Patients With Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors?
Aristotle Bamias et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
Jean Philippe Arnault et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Maurizio Zangari et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action
Alok A. Khorana et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Anorexia-Cachexia Syndrome: A Systematic Review of the Role of Dietary Polyunsaturated Fatty Acids in the Management of Symptoms, Survival, and Quality of Life
Paolo Mazzotta et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2009)
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
Caroline Robert et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Cardiovascular toxicity caused by cancer treatment: strategies for early detection
Renske Altena et al.
LANCET ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
Sanjaykumar Hapani et al.
LANCET ONCOLOGY (2009)
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Francesco Torino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Search for Evidence-Based Approaches for the Prevention and Palliation of Hand-Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)
Roger Anderson et al.
ONCOLOGIST (2009)
Quantifying the impact of standardized assessment and symptom management tools on symptoms associated with cancer-induced anorexia cachexia syndrome
Inga M. Andrew et al.
PALLIATIVE MEDICINE (2009)
Response to Sorafenib After Sunitinib-Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature
Michael K. K. Wong et al.
PHARMACOTHERAPY (2009)
Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue
Ming Hui Chen
Current Cardiology Reports (2009)
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
I. Tamaskar et al.
ANNALS OF ONCOLOGY (2008)
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
M. L. Telli et al.
ANNALS OF ONCOLOGY (2008)
Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease
Emmanuella Guenova et al.
ARCHIVES OF DERMATOLOGY (2008)
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
David S. Hong et al.
ARCHIVES OF DERMATOLOGY (2008)
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
Julien Autier et al.
ARCHIVES OF DERMATOLOGY (2008)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
Heart failure associated with sunitinib malate - A multitargeted receptor tyrosine kinase inhibitor
Aarif Y. Khakoo et al.
CANCER (2008)
Prevention of venous thromboembolism
William H. Geerts et al.
CHEST (2008)
Cardiotoxicity of the new cancer therapeutics -: mechanisms of, and approaches to, the problem
Thomas Force et al.
DRUG DISCOVERY TODAY (2008)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
The oncologist's view: Targeted therapies in advanced renal cell carcinoma
Joaquim Bellmunt
EUROPEAN UROLOGY SUPPLEMENTS (2008)
Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma
Jan Roigas
EUROPEAN UROLOGY SUPPLEMENTS (2008)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Evaluation and management of treatment-related diarrhea in patients with advanced cancer: A review
Nathan I. Cherny
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2008)
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
Vitaly Margulis et al.
JOURNAL OF UROLOGY (2008)
Cardiotoxicity associated with sunitinib - Reply
Ming Hui Chen et al.
LANCET (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
Home blood-pressure monitoring in patients receiving sunitinib
Michel Azizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Mario E. Lacouture et al.
ONCOLOGIST (2008)
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Thomas E. Hutson et al.
ONCOLOGIST (2008)
A randomized, double-blind, placebo-controlled trial of a β-hydroxyl β-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)
Lawrence Berk et al.
SUPPORTIVE CARE IN CANCER (2008)
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
S. E. Rosenbaum et al.
SUPPORTIVE CARE IN CANCER (2008)
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
B. D. Badgwell et al.
ANNALS OF ONCOLOGY (2008)
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Jeanine M. Roodhart et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
C. Porta et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
Gary H. Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Chemotherapy agents and hypertension: A focus on angiogenesis blockade
Manish Jain et al.
CURRENT HYPERTENSION REPORTS (2007)
2007 guidelines for the management of arterial hypertension
Giuseppe Mancia et al.
JOURNAL OF HYPERTENSION (2007)
Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors
L. Y. Dirix et al.
ANNALS OF ONCOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pain management, supportive and palliative care in patients with renal cell carcinoma
Jeffrey S. Turner et al.
BJU INTERNATIONAL (2007)
Nursing Considerations of Bevacizumab Use in Multiple Tumor Types
Barbara Holmes Gobel
ONCOLOGY NURSING FORUM (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Keratoacanthomas associated with sorafenib therapy
Heidi H. Kong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib
Oliver Ranze et al.
ONKOLOGIE (2007)
Managing side effects of angiogenesis inhibitors in renal cell carcinoma
Viktor Gruenwald et al.
ONKOLOGIE (2007)
Effect of regular phosphodiesterase type 5 inhibition in hypertension
James J. Oliver et al.
HYPERTENSION (2006)
Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia
Kenneth C. H. Fearon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway
Shin-ichiro Miura et al.
HYPERTENSION RESEARCH (2005)
Recommended guidelines for the treatment of cancer treatment-induced diarrhea
AB Benson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
MS Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
